先后遭遇股价暴击,“减肥双雄”感受华尔街的“躁动”

华尔街见闻
Aug 08

在高速增长的GLP-1减肥药市场,即便是行业领导者也无法高枕无忧。诺和诺德(Novo Nordisk)与礼来(Eli Lilly)这对市场双雄,强劲的财务数据已不足以支撑他们的股价,华尔街的极高期望正让市场变得异常敏感,任何一丝不及预期的消息都可能引发剧烈的抛售。本周,这种紧张关系体现得淋漓尽致。诺和诺德在公布第二季度销售额同比增长18%至240亿美元后,周三股价依然下跌3.9%。这家丹麦公司此前...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10